ImmunityBio Shares Retreat Despite Strong Commercial Momentum

ImmunityBio's ANKTIVA therapy saw 700% revenue growth in 2025, beating Q4 EPS estimates. Despite this, the stock fell nearly 10% as investors took profits.

ImmunityBio's latest financial results reveal explosive revenue growth for its flagship therapy, ANKTIVA, in 2025. However, the market's reaction was one of profit-taking, sending the stock lower even as the company surpassed quarterly earnings expectations. This divergence raises questions about the sustainability of the recent pullback.

Market Reaction Contrasts with Operational Success

Despite the positive operational updates, ImmunityBio's equity closed the latest session down 9.85% at $9.02. Trading volume was elevated, exceeding 16.5 million shares. This decline followed a period of strength earlier in the week, with the stock having reached an intraday high of $10.44 on Monday. Market commentary links the move to a broader shift toward caution among investors. The near-term trajectory for the share price is now seen as heavily dependent on the pace of the company's international commercial execution.

Financial Performance: A Year of Exponential Growth

The annual figures, released yesterday, show that ANKTIVA generated net product revenue of $113 million for 2025. This represents an increase of approximately 700% compared to the prior year, driven by a 750% surge in units sold. For the fourth quarter alone, net product revenue stood at $38.3 million.

On the bottom line, the company reported a Q4 loss per share of $0.06, which was better than the consensus analyst expectation for a loss of $0.11 per share. ImmunityBio ended the period with a solid financial position, holding $242.8 million in cash, cash equivalents, and marketable securities.

Regulatory and Commercial Expansion Gains Pace

A core growth driver remains the global rollout of ANKTIVA. The therapy received conditional marketing authorization from the European Commission in February. Furthermore, the Saudi Food and Drug Authority approved ANKTIVA in combination with checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer.

To support its Middle Eastern expansion, ImmunityBio established a commercial partnership with Biopharma and Cigalah Healthcare and formed a wholly-owned subsidiary in Saudi Arabia. The launch of commercial distribution in the region is targeted to occur within 60 days of the recent regulatory announcements. The company also indicated that its dialogue with regional authorities has opened pathways for additional regulatory submissions, including a package for a recombinant BCG product aimed at addressing global supply shortages.

Clinical Pipeline Delivers Encouraging Data

The company also reported progress across its clinical development programs. Patient recruitment has been completed for the randomized QUILT-2.005 study, which involves 366 BCG-naive patients. A regulatory agency-requested interim analysis demonstrated a complete response rate of 84% at nine months for the combination therapy, compared to 52% in the control group. Based on these results, ImmunityBio is preparing to submit a Biologics License Application in the fourth quarter of 2026.

Within its lung cancer program, the ongoing Phase 2b QUILT-3.055 study provided data on patients with checkpoint inhibitor relapsed/refractory non-small cell lung cancer, showing a median overall survival of 14.1 months.

The commercial footprint for the company's central therapy continues to widen, with approvals now secured in 33 countries worldwide.